NEJM Evidence Impact Factor in 2026: Does It Have a JIF Yet?
New England Journal of Medicine impact factor is 78.5. See the current rank, quartile, and what the number actually means before you submit.
Associate Professor, Clinical Medicine & Public Health
Author context
Specializes in clinical and epidemiological research publishing, with direct experience preparing manuscripts for NEJM, JAMA, BMJ, and The Lancet.
Journal evaluation
Want the full picture on New England Journal of Medicine?
See scope, selectivity, submission context, and what editors actually want before you decide whether New England Journal of Medicine is realistic.
A fuller snapshot for authors
Use New England Journal of Medicine's impact factor as one signal, then stack it against selectivity, editorial speed, and the journal guide before you decide where to submit.
What this metric helps you decide
- Whether New England Journal of Medicine has the citation profile you want for this paper.
- How the journal compares to nearby options when prestige or visibility matters.
- Whether the citation upside is worth the likely selectivity and process tradeoffs.
What you still need besides JIF
- Scope fit and article-type fit, which matter more than a high number.
- Desk-rejection risk, which impact factor does not predict.
- Timeline and cost context.
How authors actually use New England Journal of Medicine's impact factor
Use the number to place the journal in the right tier, then check the harder filters: scope fit, selectivity, and editorial speed.
Use this page to answer
- Is New England Journal of Medicine actually above your next-best alternatives, or just more famous?
- Does the prestige upside justify the likely cost, delay, and selectivity?
- Should this journal stay on the shortlist before you invest in submission prep?
Check next
- Acceptance rate: <5%. High JIF does not tell you how hard triage will be.
- First decision: 21 day. Timeline matters if you are under a grant, job, or revision clock.
- Publishing cost and article type, since those constraints can override prestige.
Quick answer: As of the current internal JCR 2024 reference table, NEJM Evidence does not appear with a Journal Impact Factor listing. That does not automatically mean the journal is weak. It means you should evaluate the journal with a different decision framework than you would use for an established flagship with a listed JIF.
Quick Decision Cue
This page is useful if... | This page is not enough if... |
|---|---|
your committee or co-authors keep asking whether NEJM Evidence has a listed JIF yet | you already know the metric question and need to decide between concrete journal targets |
you need to explain why no listed JIF is not the same as a quality problem | your institution requires a listed JIF for promotion or grant review and you have not confirmed policy |
you are choosing between brand strength and metric availability | the paper is career-critical and the committee is rigidly metric-driven |
The absence of a JIF does not reflect the journal's quality or reach. NEJM Evidence is published by the NEJM Group and covers high-quality clinical trials and evidence synthesis. The practical issue is not legitimacy. It is how your field and committee will interpret a newer title without a listed JIF.
The absence of a JIF doesn't reflect the journal's quality or reach. NEJM Evidence is published by the NEJM Group, edited by senior editors with NEJM pedigree, and covers high-quality clinical trials and evidence synthesis at the same standards as its parent journal.
NEJM Evidence impact factor trend
NEJM Evidence launched in January 2022 and does not yet appear with a JIF listing in the Clarivate JCR 2024 database. JIF calculations require at least two years of citation history within the JCR system, and journals must complete a formal application and evaluation process. NEJM Evidence is indexed in Scopus with a Q1 SJR of 1.154, confirming strong early citation performance relative to established evidence journals. A JIF listing is expected within the next 1-2 annual JCR cycles as the citation record accumulates.
For current planning, use the Scopus metrics and NEJM Group pedigree as the proxy for journal standing until a JIF is assigned.
Submit If / Think Twice If
Submit if:
- the manuscript is a randomized clinical trial with definitive findings in clinical medicine that doesn't clear NEJM's threshold but deserves the NEJM Group's editorial standards and audience
- the work is a large systematic review or meta-analysis with clear practice implications and would fit naturally within the NEJM editorial ecosystem
- your institution accepts Scopus Q1 standing and NEJM Group pedigree in lieu of a listed JCR impact factor
- speed matters: NEJM Evidence has faster turnaround than the parent journal
Think twice if:
- your promotion case requires a listed JIF and your institution is rigidly metric-driven, confirm policy before submitting
- the paper would be competitive at JAMA or BMJ, which have listed JIFs and equivalent or higher prestige
- the work is basic science or narrowly specialist, NEJM Evidence's scope is clinical trials and evidence synthesis
What Is NEJM Evidence?
NEJM Evidence is a digital-first clinical journal focused on clinical trials, systematic reviews, and original research in evidence-based medicine. It was launched to address a gap: the original NEJM's limited space relative to the volume of high-quality clinical research being produced.
Key characteristics:
- Publisher: Massachusetts Medical Society (same as NEJM)
- Editorial identity: senior clinical editors within the NEJM Group
- Launch date: January 2022
- Format: Digital-only, open access option available
- Scope: Clinical trials, systematic reviews, clinical epidemiology, health services research
Why No JIF Yet (and What That Means)
The practical point is simple: in the current internal JCR 2024 reference layer we use for metric validation, NEJM Evidence is not listed with a JIF. Until that changes, you should not treat the journal like a normal impact-factor page.
For authors, this creates a practical consideration:
Some promotion committees and grant applications specifically require a listed JIF. If your institution uses JIF as a formal filter for promotion cases, submitting to NEJM Evidence carries a risk because reviewers may not count it the same way they would count a journal with a current listed metric.
If your institution is more flexible about journal quality vs. listed metrics, NEJM Evidence's pedigree and editorial standards should carry weight equivalent to other high-quality clinical journals.
Available Metrics for NEJM Evidence
Even without a formal JCR listing, NEJM Evidence isn't operating in a data vacuum. Here's what's available from other indexing services.
Metric | Value | Source |
|---|---|---|
JCR Impact Factor | Not listed | Clarivate JCR 2024 |
Scopus SJR | 1.154 | SCImago (computed 2025) |
Scopus Quartile | Q1 | SCImago |
PubMed | Indexed | NLM |
Launch year | 2022 | NEJM Group |
The Scopus SJR of 1.154 and Q1 quartile confirm that citation databases are tracking the journal and that its early citation performance is strong. For committees that accept Scopus metrics alongside or instead of JCR, this data point can help.
NEJM Evidence vs NEJM, JAMA, BMJ, and Lancet
This is the comparison that matters for clinical researchers deciding where to send a trial or systematic review.
Journal | IF (2024) | Acceptance Rate | Scope | Review Speed |
|---|---|---|---|---|
NEJM | 78.5 | ~5% | Practice-changing clinical trials, landmark studies | 2-4 weeks to first decision |
NEJM Evidence | No JIF yet | Not published | High-quality clinical trials, evidence synthesis | Faster than NEJM |
JAMA | 55.0 | ~5-7% | Broad clinical medicine, trials, US policy relevance | 2-4 weeks to first decision |
BMJ | 42.7 | ~7% | Clinical research, health policy, global health | 3-6 weeks to first decision |
Lancet | 88.5 | ~5% | Global health, major international trials | 2-4 weeks to first decision |
Annals of Internal Medicine | ~21 | ~8-10% | Internal medicine, clinical guidelines, systematic reviews | 4-6 weeks to first decision |
NEJM Evidence vs NEJM: The parent journal (IF 78.5) is the most selective general medical journal in the world. NEJM Evidence was created because NEJM's limited space meant strong clinical trials were being turned away. If NEJM desk-rejects your trial, NEJM Evidence is the natural next step, you stay within the NEJM Group ecosystem, keep the editorial pedigree, and reach an overlapping readership. The practical difference is that NEJM Evidence doesn't yet carry the metric weight that hiring committees expect from NEJM itself.
NEJM Evidence vs JAMA: JAMA (IF 55.0) has a listed JIF and established committee recognition. If your institution requires a listed JIF for promotion, JAMA is the safer metric choice right now. But JAMA and NEJM Evidence serve slightly different audiences: JAMA skews toward US health policy and broader clinical medicine, while NEJM Evidence is more tightly focused on clinical trials and evidence synthesis. The fit question matters more than the metric gap.
NEJM Evidence vs BMJ: BMJ (IF 42.7) has strong global reach and a more flexible scope that includes health services research and policy alongside clinical trials. For international trials with global health implications, BMJ may be a better audience fit. For US-focused or trial-centric work, NEJM Evidence's editorial identity is a closer match.
NEJM Evidence vs Lancet: Lancet (IF 88.5) is the other top-tier option for major international trials. If the trial has global public health significance, Lancet is the natural target. NEJM Evidence isn't competing with Lancet for that tier of work, it's competing for the next band down, where the trial is strong but not practice-changing at a global scale.
NEJM Evidence sits between NEJM (harder to get into, bigger splash) and mid-tier clinical journals. It's a strong option for rigorous clinical work that might not clear NEJM's threshold but deserves the NEJM Group's reach and audience.
What Pre-Submission Reviews Reveal About NEJM Evidence Submissions
In our pre-submission review work on manuscripts targeting NEJM Evidence, three patterns account for most of the issues we identify before submission.
Submitting without confirming institutional metric policy. The single most consequential issue we see is researchers submitting to NEJM Evidence without first verifying whether their institution's promotion and tenure process accepts journals without a listed JIF. Because NEJM Evidence is new and the JIF has not yet been assigned, some metric-driven promotion committees either discount publications here or require additional explanation. We have seen career-stage mismatches where an early-career researcher submitted their most important study to NEJM Evidence, which was clinically rigorous and well-placed, but faced a T&P committee that required a listed JIF and did not know how to credit the publication. The fix is simple: confirm your promotion criteria before submitting career-critical work to any journal without a listed JIF.
Papers that belong at JAMA or BMJ but are submitted to NEJM Evidence as a "step down" from NEJM. The logic authors often apply is: "We were rejected by NEJM, so we'll try NEJM Evidence next." That reasoning works when the paper fits NEJM Evidence's scope, clinical trials, evidence synthesis, rigorous clinical epidemiology. It does not work when the paper is a broader clinical medicine study better suited to JAMA, BMJ, or Annals of Internal Medicine, journals that have listed JIFs and established committee recognition. Using NEJM Evidence as a fallback for any NEJM rejection is a scope mismatch. The paper needs to fit NEJM Evidence's specific focus on clinical trial evidence, not just the NEJM family brand.
Observational studies without rigor appropriate for the NEJM Group standard. NEJM Evidence carries the NEJM Group's editorial expectations for methodological rigor. We see observational studies submitted with the assumption that the lower selectivity compared to NEJM proper means a lower methodological bar. That assumption is wrong. NEJM Group editorial culture demands pre-specified analysis plans, appropriate sensitivity analyses, honest handling of confounding, and complete reporting of null findings. Observational studies that would pass peer review at a mid-tier clinical journal can face rejection at NEJM Evidence specifically because the methods don't meet the NEJM Group's reporting standards.
What To Check Instead Of A Missing JIF
If you need to know... | Check this |
|---|---|
whether the journal is legitimate and visible | publisher identity, indexing, and the NEJM Group editorial umbrella |
whether your institution will count it the way you expect | your promotion criteria, grant guidance, and recent committee behavior |
whether the paper belongs here instead of NEJM, JAMA, or BMJ | manuscript fit, audience, and whether the work is broad enough for a flagship decision page |
whether the tradeoff is worth it | speed, audience reach, and whether a listed JIF is strategically necessary for this manuscript |
Who Should Submit to NEJM Evidence
Good fit:
- Randomized clinical trials with definitive or substantial findings in clinical medicine
- Large systematic reviews or meta-analyses with clear practice implications
- Clinical epidemiology studies with real-world relevance to medical decision-making
- Secondary analyses of major trials that produce practice-relevant insights
Not a good fit:
- Basic science or mechanistic laboratory work
- Small observational studies without meaningful clinical sample sizes
- Case reports or case series
- Narrow disease-specific work better suited to specialist journals
The JIF Question in Context
Impact factor is a lagging indicator. It measures citation history, not current quality. NEJM Evidence is new, its editorial standards are high, and its parentage is strong. The JIF will come.
If you're choosing between NEJM Evidence and a journal that has a JIF but lower editorial standards, the JIF alone isn't a good reason to choose the lower-quality venue. Talk to your department chair or mentors about how your institution actually weighs journal prestige vs. listed metrics.
Submission Tips
- Structure your trial properly. CONSORT compliance, pre-registered protocol, and pre-specified endpoints are expected
- Clinical relevance is the filter. State the practice implication in the cover letter clearly
- NEJM Evidence has faster turnaround than NEJM. This can be a practical advantage for time-sensitive findings
- Open access option is available if your funder requires it
If You Need The Next Decision Page
If you actually need to decide... | Go here |
|---|---|
whether to aim for NEJM first | |
how selective the flagship really is | |
whether NEJM is the right brand target at all | |
whether to compare against other broad clinical flagships | |
whether you should stop debating metrics and check readiness |
More Resources
Frequently asked questions
In current JCR lookups, NEJM Evidence does not return a JIF listing.
No. JIF availability and journal legitimacy are different questions.
Use indexing status, editorial board quality, article performance, and fit with your committee's expectations.
It depends on your institution's metric culture. If JIF is mandatory for promotion, confirm policy before submitting.
Sources
Reference library
Use the core publishing datasets alongside this guide
This article answers one part of the publishing decision. The reference library covers the recurring questions that usually come next: whether the package is ready, what drives desk rejection, how journals compare, and what the submission requirements look like across journals.
Checklist system / operational asset
Elite Submission Checklist
A flagship pre-submission checklist that turns journal-fit, desk-reject, and package-quality lessons into one operational final-pass audit.
Flagship report / decision support
Desk Rejection Report
A canonical desk-rejection report that organizes the most common editorial failure modes, what they look like, and how to prevent them.
Dataset / reference hub
Journal Intelligence Dataset
A canonical journal dataset that combines selectivity posture, review timing, submission requirements, and Manusights fit signals in one citeable reference asset.
Dataset / reference guide
Peer Review Timelines by Journal
Reference-grade journal timeline data that authors, labs, and writing centers can cite when discussing realistic review timing.
Before you upload
Want the full picture on New England Journal of Medicine?
Scope, selectivity, what editors want, common rejection reasons, and submission context, all in one place.
These pages attract evaluation intent more than upload-ready intent.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Same journal, next question
Compare alternatives
Supporting reads
Want the full picture on New England Journal of Medicine?
These pages attract evaluation intent more than upload-ready intent.